No longer trading

Acquired by Biogen Inc.

The acquisition closed on May 14, 2026 (SEC 8-K 2.01). Its last closing price was on May 13, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from May 3, 2026. Source: SEC 8-K 2.01

APLS

Apellis Pharmaceuticals, Inc. APLS

NasdaqMid CapHealthcare

Final 13F Pro quality score

Final rank #849 of 2,819 · as of May 3, 2026TOP 50%

Why it scores 60Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$268.30M

Quarter to Mar 31

Net income

$18.66M

Quarter to Mar 31

Operating margin

9.9%

Quarter to Mar 31

Top Institutional Holders

as of Q2 2026
$10.2K total
IFP Advisors, Inc
$10.2K-47.3%
See all 1 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q1 2026
EDGAR

Net Income

Q1 2026
EDGAR

EPS (Diluted)

Q1 2026
EDGAR

Operating Margin

Q1 2026
EDGAR

ROIC

Q1 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/APLS

Earnings Per Share

13fpro.ai/company/APLS

Loading ratio trend…

APLS key financials by period

Reported revenue, net income and operating margin by fiscal year, from Apellis Pharmaceuticals, Inc.'s annual filings on SEC EDGAR.

Apellis Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$1.0B$22.4M5.5%
FY 2024$781.4M$-197.9M-21.1%
FY 2023$396.6M$-528.6M-130.4%
FY 2022$75.4M$-652.2M—
FY 2021$66.6M$-746.4M—
FY 2020$250.6M$-344.9M-85.3%
Source: APLS filings on SEC EDGAR →

APLS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Apellis Pharmaceuticals, Inc. (APLS): stock profile, AI score and financials

Acquired by Biogen Inc.: Apellis Pharmaceuticals, Inc. (APLS) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on May 14, 2026 (SEC 8-K 2.01). Its last closing price was on May 13, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from May 3, 2026. Apellis Pharmaceuticals, Inc. (APLS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks APLS using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q1 2026), Apellis Pharmaceuticals, Inc. reports quarterly revenue of $268.3M, net income of $18.7M, an operating margin of 9.9%. APLS trades on the Nasdaq exchange and files with the SEC under CIK 1492422. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Apellis Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1492422 →